Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome
Authors:
- Roger G. WhittakerRWRoger G. Whittaker
- David N. HerrmannDHDavid N. Herrmann
- Boglarka BansagiBBBoglarka Bansagi
- Bashar Awwad Shiekh HasanBHBashar Awwad Shiekh Hasan
- Robert Muni LofraRLRobert Muni Lofra
- Eric L. LogigianELEric L. Logigian
- Janet E. SowdenJSJanet E. Sowden
- Jorge L. AlmodovarJAJorge L. Almodovar
- J. Troy LittletonJLJ. Troy Littleton
- Stephan ZuchnerSZStephan Zuchner
- Rita HorvathRHRita Horvath
- Hanns LochmüllerHLHanns Lochmüller
- 1 December 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 85 (22) , 1964-1971
Abstract
Objectives: To describe the clinical and electrophysiologic features of synaptotagmin II (SYT2) mutations, a novel neuromuscular syndrome characterized by foot deformities and fatigable ocular and lower limb weakness, and the response to modulators of acetylcholine release. Methods: We performed detailed clinical and neurophysiologic assessment in 2 multigenerational families with dominant SYT2 mutations (c.920T>G [p.Asp307Ala] and c.923G>A [p.Pro308Leu]). Serial clinical and electrophysiologic assessments were performed in members of one family treated first with pyridostigmine and then with 3,4-diaminopyridine. Results: Electrophysiologic testing revealed features indicative of a presynaptic deficit in neurotransmitter release with posttetanic potentiation lasting up to 60 minutes. Treatment with 3,4-diaminopyridine produced both a clinical benefit and an improvement in neuromuscular transmission. Conclusion: SYT2 mutations cause a novel and potentially treatable complex presynaptic congenital myasthenic syndrome characterized by motor neuropathy causing lower limb wasting and foot deformities, with reflex potentiation following exercise and a uniquely prolonged period of posttetanic potentiation.Keywords
This publication has 27 references indexed in Scilit:
- Hexosamine Biosynthetic Pathway Mutations Cause Neuromuscular Transmission DefectThe American Journal of Human Genetics, 2011
- Differential regulation of synchronous versus asynchronous neurotransmitter release by the C2 domains of synaptotagmin 1Proceedings of the National Academy of Sciences, 2010
- Synaptotagmin Has an Essential Function in Synaptic Vesicle Positioning for Synchronous Release in Addition to Its Role as a Calcium SensorNeuron, 2009
- Presynaptic Release Probability and Readily Releasable Pool Size Are Regulated by Two Independent Mechanisms during Posttetanic Potentiation at the Calyx of Held SynapseJournal of Neuroscience, 2008
- Synaptotagmin-2 Is Essential for Survival and Contributes to Ca2+Triggering of Neurotransmitter Release in Central and Neuromuscular SynapsesJournal of Neuroscience, 2006
- Available treatment options for the management of Lambert-Eaton myasthenic syndromeExpert Opinion on Pharmacotherapy, 2006
- Molecular genetics of distal hereditary motor neuropathiesHuman Molecular Genetics, 2004
- AAEM case report #3: Myasthenia gravisMuscle & Nerve, 1991
- 3,4-Diaminopyridine in the Treatment of Lambert–Eaton Myasthenic SyndromeNew England Journal of Medicine, 1989
- Prolongation of post‐tetanic facilitation in infant botulismMuscle & Nerve, 1982